Tarsons Products reported a 21% year-on-year revenue growth in Q1 FY27. However, rising input costs and higher depreciation affected profitability. The company also delayed the commissioning of its Panchla facility.
Tarsons Products Q1 FY27 Performance
Consolidated Revenue: Rs 110.2 crore (+21% YoY) Standalone Revenue: Rs 86.1 crore (+21% YoY) Reader Takeaway: Resilient revenue growth faces margin headwinds and delayed capacity expansion. ## What just happened Tarsons Products posted a strong Q1 FY27 with consolidated revenue reaching Rs 110.2 crore, a 21% increase year-on-year. Standalone revenue also grew 21% to Rs 86.1 crore. Despite the revenue jump, profitability was impacted by a 25-50% spike in polymer prices and increased depreciation and interest costs from recent capital expenditure. ## Why this matters The revenue growth indicates healthy demand for Tarsons' products, both domestically and internationally. However, the margin pressure highlights the challenge of rising input costs, which management is struggling to fully pass on, especially in export markets. The delay in commissioning the Panchla facility to H2 FY27 also pushes back expected revenue contributions from this expansion. ## The backstory The company is in the final stages of a significant capacity expansion. The Panchla facility, a key part of this expansion, was initially expected to be commissioned sooner. The company carries a gross debt of approximately Rs 380 crore. ## What changes now While revenue momentum is positive, the focus shifts to managing costs and timelines. The company aims to reduce debt by Rs 40-50 crore year-on-year. Management is prioritizing maintenance Capex and completion of the ongoing expansion rather than initiating new large projects. ## Risks to watch Key concerns include ongoing volatility in raw material costs (polymers), which directly affect margins. The delayed commissioning of the Panchla facility is a crucial factor for future revenue ramp-up. Geopolitical tensions and global tariff uncertainties remain risks for the export business. ## Peer comparison While specific peer data isn't in the filing, the sector generally faces similar challenges regarding raw material costs and supply chain disruptions impacting margins. ## Context metrics (time-bound) Consolidated Revenue: Rs 110.2 crore (Q1 FY27) vs. Rs ~91 crore (Q1 FY26) Standalone Revenue: Rs 86.1 crore (Q1 FY27) vs. Rs ~71.3 crore (Q1 FY26) Standalone Gross Margin: 67.1% (Q1 FY27) Gross Debt: ~Rs 380 crore Net Debt: ~Rs 330-340 crore Panchla Commissioning: Shifted to H2 FY27 FY27 Debt Reduction Target: ~Rs 40-50 crore ## What to track next Investors will be watching for stabilization in raw material prices, the successful commissioning and ramp-up of the Panchla facility, and the company's ability to improve margins amidst cost pressures. The 'cell culture' segment is also a key area to monitor for diversification.
